Table 2.

Grade 1 and 2 adverse events experienced by patients enrolled on trial.

	N (%)
Gastrointestinal
Abdominal pain	1 (6.3%)
Anorexia	3 (18.8%)
Diarrhea	12 (75%)
Dysgeusia	2 (12.5%)
Dyspepsia	2 (12.5%)
Gastroesophageal reflux	1 (6.3%)
Mucositis, oral	1 (6.3%)
Nausea	4 (25%)
Vomiting	2 (12.5%)
Weight loss	1 (6.3%)
Skin/Dermatologic
Alopecia	1 (6.3%)
Pruritis	1 (6.3%)
Rash	3 (18.8%)
Neurological/Musculoskeletal
Headache	1 (6.3%)
Muscle cramps/myalgias	3 (18.8%)
Paresthesia	1 (6.3%)
Cardiac
Palpitations	2 (12.5%)
Sinus tachycardia	1 (6.3%)
Constitutional
Fatigue	3 (18.8%)
Malaise	1 (6.3%)
Other
Cough	1 (6.3%)
Infusion-related reaction	3 (18.8%)
Nasal congestion/mucositis	2 (12.5%)
Anemia	1 (6.3%)